These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25833004)

  • 1. Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease.
    Wagner JA; Ball JR
    Clin Pharmacol Ther; 2015 Jul; 98(1):12-5. PubMed ID: 25833004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine.
    Lyman GH; Moses HL
    N Engl J Med; 2016 Jul; 375(1):4-6. PubMed ID: 27353537
    [No Abstract]   [Full Text] [Related]  

  • 3. Codevelopment of genome-based therapeutics and companion diagnostics: insights from an Institute of Medicine roundtable.
    McCormack RT; Armstrong J; Leonard D
    JAMA; 2014 Apr; 311(14):1395-6. PubMed ID: 24522512
    [No Abstract]   [Full Text] [Related]  

  • 4. IOM outlines framework for postmarket safety.
    Reinke T
    Manag Care; 2012 Aug; 21(8):10-1. PubMed ID: 22957462
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarkers and heart disease.
    Albert MA
    J Clin Sleep Med; 2011 Oct; 7(5 Suppl):S9-11. PubMed ID: 22003335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review and critique of the Institute of Medicine report "the future of drug safety".
    Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):158-61. PubMed ID: 17259941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA unveils 25 initial 510(k) changes, refers controversial recommendations to the Institute of Medicine (IOM).
    Gilmore M; Hylak-Reinholtz JJ
    Health Care Law Mon; 2011 Jun; 2011(6):2-7. PubMed ID: 21748924
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing recommendations from the IOM's quality chasm report.
    Staggers N
    J Healthc Inf Manag; 2004; 18(1):30-5. PubMed ID: 14971077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA and the IOM report.
    Galson SK
    N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
    [No Abstract]   [Full Text] [Related]  

  • 10. IOM offers five recommendations to mend ailing health care system.
    Health Care Strateg Manage; 2003 Feb; 21(2):15. PubMed ID: 12622046
    [No Abstract]   [Full Text] [Related]  

  • 11. Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations.
    Yetley EA; DeMets DL; Harlan WR
    Am J Clin Nutr; 2017 Nov; 106(5):1175-1189. PubMed ID: 29021287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of state health department compliance with the recommendations of the Institute of Medicine report, The Future of Public Health.
    Scutchfield FD; Beversdof CA; Hiltabiddle SE; Violante T
    J Public Health Policy; 1997; 18(1):13-29. PubMed ID: 9170786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 14. The Institute of Medicine report "Unequal Treatment": implications for academic health centers.
    Betancourt JR; Maina AW
    Mt Sinai J Med; 2004 Oct; 71(5):314-21. PubMed ID: 15543432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    Jones JK
    Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xenotransplants. IOM backs cautious experimentation.
    Kaiser J
    Science; 1996 Jul; 273(5273):305-6. PubMed ID: 8685715
    [No Abstract]   [Full Text] [Related]  

  • 17. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 18. Imaging biomarkers as surrogate endpoints for drug development.
    Richter WS
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33 Suppl 1():6-10. PubMed ID: 16721568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 20. The Central Service for the Chronically Ill; Third annual report of the committee to the Board of Governors of the Institute of Medicine of Chicago, December 10, 1946.
    NICHOLSON E; PETERSEN WF
    Proc Inst Med Chic; 1946 Dec; 16(9):280-2. PubMed ID: 20287325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.